Harvard-Affiliated Ketamine Research: Reading the Evidence Carefully

Research affiliations can help you locate a study, but they cannot tell you whether its findings apply to a proposed treatment. A useful example is a 2023 depression trial whose authors included researchers affiliated with Harvard Medical School.

Important: Compounded ketamine is not FDA-approved. FDA has not reviewed these products for safety, effectiveness, or quality before marketing. Ketamine is not FDA-approved for psychiatric conditions. Compounded nasal spray is different from FDA-approved esketamine (Spravato), which is administered in certified healthcare settings. Read FDA's explanation of compounded drugs.

What did the trial compare?

The multi-center randomized study by Anand and colleagues compared monitored intravenous ketamine with electroconvulsive therapy in adults with treatment-resistant major depression without psychosis. It concluded that ketamine met the trial's noninferiority criterion for the initial response outcome.

The study did not test a compounded at-home nasal spray. Its findings do not establish a preferred treatment for every patient or a general safety advantage for ketamine.

What does “noninferiority” mean?

A noninferiority trial asks whether one treatment falls within a predefined acceptable margin compared with another on a particular outcome. Meeting that criterion does not mean the treatments have identical effects, identical risks, or interchangeable uses. It also does not establish that one is universally better.

What else matters when reading a result?

Ask how participants were selected, whether they knew their treatment assignment, what symptoms were measured, and how long they were followed. Review adverse effects and the people who did not complete treatment, as well as the main response finding.

An early endpoint and a long-term care decision answer different questions. A clinician needs to consider prior treatment, symptom severity, medical conditions, and the support available in the proposed setting.

How should this affect a consultation?

Bring a link to the actual study rather than relying on a headline or a summary that says “Harvard proves ketamine works.” Ask what it supports, what it leaves uncertain, and which alternatives are reasonable for you.

Research conducted by Harvard-affiliated authors is not an endorsement of Bliss Mist Rx, a particular pharmacy, or a compounded formulation. Outcomes from an intravenous study should not become an advertised success rate for home nasal spray. You deserve a clear explanation of that difference before making a treatment decision.

Risks and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Abuse, misuse, dependence, worsening psychiatric symptoms, and urinary or bladder problems are additional concerns. A prescription or lower dose does not eliminate these risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to a serious reaction. Virtual visits and follow-up support do not provide the same monitoring as an onsite healthcare team. Discuss your medications, health history, monitoring needs, and emergency plan with your clinician.

Discuss your options

Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. A licensed clinician determines whether treatment is appropriate. A consultation does not guarantee a prescription. If prescribed, medication is dispensed by an independent, appropriately licensed compounding pharmacy.

Book a Free Virtual Appointment or Follow-Up.

This article is general education and does not replace individualized medical advice.

Sources and further reading

• FDA: compounding questions and answers
• FDA: Ketalar prescribing information
• FDA: Spravato prescribing information
• Anand and colleagues: 2023 intravenous ketamine versus ECT trial